The expression of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor protein and mRNA in benign, borderline and malignant ovarian neoplasia

International Journal of Oncology

Volumn 34, Issue 6, 2009, Pages 1583-1591

  Song, Jae Yen ^a   Chen, Keun Young ^a   Kim, Sue Yeon ^a   Kim, Mee Ran ^a   Ryu, Ki Sung ^a   Cha, Jung Ho ^a   Kang, Chang Suk ^a   MacLaughlin, David T ^b   Kim, Jang Heub ^a  

^a The Catholic University of Korea   (South Korea)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Immuno histochemistry; In situ hybridization; M llerian inhibiting substance; M llerian inhibiting substance anti M llerian hormone type II receptor; Ovarian neoplasia

Indexed keywords

MESSENGER RNA; MUELLERIAN INHIBITING FACTOR;

ARTICLE; CONTROLLED STUDY; EPITHELIUM TUMOR; GERM CELL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; SEX CORD TUMOR; TISSUE SPECIFICITY; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION;

ANTI-MULLERIAN HORMONE; CARCINOMA; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION; OVARIAN NEOPLASMS; OVARY; RECEPTORS, PEPTIDE; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEX CORD-GONADAL STROMAL TUMORS; TISSUE ARRAY ANALYSIS;

EID: 67649425215     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000288     Document Type: Article

References (33)

1. MacLaughlin DT and Donahoe PK: Mullerian inhibiting substance: a potential nontoxic, naturally occurring therapeutic agent for certain human cancers. In: Transforming Growth Factor-Beta in Cancer Therapy. Jakowlew S (ed). Humana Press, Totowa (NJ), pp333-353, 2008.
2. Catlin EA, Powell SM, Manganaro TF, Hudson PL, Ragin RC, Epstein J and Donahoe PK: Sex-specific fetal lung development and Müllerian inhibiting substance. Am Rev Respir Dis 141: 466-470, 1990.
3. Lee MM, Donahoe PK, Hasegawa T, Silverma B, Crist GB, Best S, Hasegawa Y, Noto RA, Schoenfeld D and MacLaughlin DT: Müllerian inhibiting substance in humans: normal levels from infancy to adulthood. J Clin Endocrinol Metab 81: 571-576, 1996.
4. Kim JH, Seibel MM, MacLaughlin DT, Donahoe PK, Ransil BJ, Hametz PA and Richards CJ: The inhibitory effects of Müllerian inhibiting substance on epidermal growth factor induced proliferation and progesterone production of human granulosaluteal cells. J Clin Endocrinol Metab 75: 911-917, 1992.
5. Kuroda T, Lee MM, Ragin RC, Hirobe S and Donahoe PK: Müllerian inhibiting substance production and cleavage is modulated by goandotropins and steriods. Endocrinology 129: 2985-2992, 1991.
6. Baarends WM, Uilenbroek JT, Kramer P, Hoogerbrugge JW, van Leeuwen EC, Themmen AP and Grootegoed JA: Anti-Müllerian hormone and anti-Müllerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development, the estrous cycle, and gonadotropin-induced follicle growth. Endocrinology 136: 4951-4962, 1995.
7. Behringer RR, Cate RL, Froelick GJ, Palmiter RD and Brinster RL: Abnormal sexual development in transgenic mice chronically expressing Müllerian inhibiting substance. Nature 345: 167-170, 1990.
8. Chin T, Parry RL and Donahoe PK: Human Müllerian inhibiting substance inhibits tumor growth in vitro and in vivo. Cancer Res 51: 2101-2106, 1991.
9. Masiakos PT, MacLaughlin DT, Maheswaran S, Teixeira J, Fuller AF Jr, Shah PC, Kehas DJ, Kenneally MK, Dombkowski DM, Ha TU, Preffer FI and Donahoe PK: Human ovarian cancer, cell lines, and primary ascites cells express the human Müllerian inhibiting substance (MIS/AMH) type II receptor, bind, and are responsive to MIS/AMH. Clin Cancer Res 5: 3488-3499, 1999.
10. Ha TU, Segev DL, Barbie D, Masiakos PT, Tran TT, Dombkowski D, Glander M, Clarke TR, Lorenzo HK, Donahoe PK and Maheswaran S: Müllerian inhibiting substance inhibits ovarian cell growth through an pRb-independent mechanism. J Biol Chem 275: 37101-37109, 2000.
11. Stephen AE, Pearsall LA, Christian BP, Donahoe PK, Vacanti JP and MacLaughlin DT: Highly purified Müllerian inhibiting substance inhibits human ovarian cancer in vivo. Clin Cancer Res 8: 2640-2646, 2002.
12. Segev DL, Ha TU, Tran TT, Kenneally M, Harkin P, Jung M, MacLaughlin DT, Donahoe PK and Maheswaran S: Müllerian inhibiting substance inhibits breast cancer cell growth through an NFκB-mediated pathway. J Biol Chem 275: 28371-28379, 2000.
13. Barbie TU, Barbie DA, MacLaughlin DT, Maheswaran S and Donahoe PK: Müllerian inhibiting substance inhibits cervical cancer cell growth via a pathway involving p130 and p107. Proc Natl Acad Sci USA 100: 15601-15606, 2003.
14. Renaud EJ, MacLaughlin DT, Oliva E, Rueda BR and Donahoe PK: Endometrial cancer is a receptor-mediated target for Müllerian Inhibiting Substance. Proc Natl Acad Sci USA 102: 111-116, 2005.
15. Gouedard L, Chen YG, Thevenet L, Racine C, Borie S, Lamarre I, Josso N, Massague J and di Clemente N: Engagement of bone morphogenetic protein type IB receptor and Smad1 signaling by anti-Müllerian hormone and its type II receptor. J Biol Chem 275: 27973-27978, 2000.
16. Clarke TR, Hoshiya Y, Yi SE, Liu X, Lyons KM and Donahoe PK: Müllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces Smad6 expression. Mol Endocrinol 15: 946-959, 2001.
17. Visser JA, Olaso R, Verhoef-Post M, Kramer P, Themmen AP and Ingraham HA: The serine/threonine transmembrane receptor ALK2 mediates Müllerian inhibiting substance signaling. Mol Endocrinol 15: 936-945, 2001.
18. Teixeira J, Maheswaran S and Donahoe PK: Müllerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications. Endocr Rev 22: 657-674, 2001.
19. Josso N and di Clemente N: Transduction pathway of anti-Müllerian hormone, a sex-specific member of the TGF-beta family. Trends Endocrinol Metab 14: 91-97, 2003.
20. di Clemente N, Josso N, Gouedard L and Belville C: Components of the anti-Müllerian hormone signaling pathway in gonads. Mol Cell Endocrinol 211: 9-14, 2003.
21. Segev DL, Hoshiya Y, Hoshiya M, Tran TT, Carey JL, Stephen AE, MacLaughlin DT, Donahoe PK and Maheswaran S: Müllerian-inhibiting substance regulates NF-κB signaling in the prostate in vitro and in vivo. Proc Natl Acad Sci USA 99: 239-244, 2002.
22. Xavier F and Allard S: Anti-Mullerian hormone, beta-catenin and Müllerian duct regression. Mol Cell Endocrinol 211: 115-121, 2003.
23. Allard S, Adin P, Gouedard L, di Clemente N, Josso N, Orgebin-Crist MC, Picard JY and Xavier F: Molecular mechanisms of hormone-mediated Mullerian duct regression: involvement of beta-catenin. Development 127: 3349-3360, 2000.
24. Segev DL, Hoshiya Y, Stephen AE, Hoshiya M, Tran TT, MacLaughlin DT, Donahoe PK and Maheswaran S: Müllerian inhibiting substance regulates NFκB signaling and growth of mammary epithelial cells in vivo. J Biol Chem 276: 26799-26806, 2001.
25. Bakkum-Gamez JN, Aletti G, Lewis KA, Keeney GL, Thomas BM, Navarro-Teulon I and Cliby WA: Müllerian inhibiting substance type II receptor (MIS/AMHIIR): a novel, tissue-specific target expressed by gynecologic cancers. Gynecol Oncol 108: 141-148, 2008.
26. Salhi I, Cambon-Roques S, Lamarre I, Laune D, Molina F, Pugniere M, Pourquier D, Gutowski M, Picard JY, Xavier F, Pelegrin A and Navarro-Teulon I: The anti-Müllerian hormone type II receptor: insights into the binding domains recognized by a monoclonal antibody and the natural ligand. Biochem J 379: 785-793, 2004.
27. Salom E, Almeida Z and Mirhashemi R: Management of recurrent ovarian cancer: evidence-based decisions. Curr Opin Oncol 14: 519-527, 2002.
28. Hoshiya Y, Gupta V, Segev DL, Hoshiya M, Carey JL, Sasur LM, Tran TT, Ha TU and Maheswaran S: Müllerian inhibiting substance induces NFkB signaling in breast and prostate cancer cells. Mol Cell Endocrinol 211: 43-49, 2003.
29. Gupta V, Carey JL, Kawakubo H, Muzikansky A, Green JE, Donahoe PK, MacLaughlin DT and Maheswaran S: Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model. Proc Natl Acad Sci USA 102: 3219-3224, 2005.
30. Gustafson ML, Lee MM, Scully RE, Moncure AC, Hirakawa T, Goodman A, Muntz HG, Donahoe PK, MacLaughlin DT and Fuller AF Jr: Müllerian inhibiting substance as a marker for ovarian sex cord tumor. N Engl J Med 326: 466-471, 1992.
31. Josso N: Pediatric applications of anti-Müllerian hormone research. Horm Res 43: 243-248, 1995.
32. Lane AH, Lee MM, Fuller AF, Kehas DJ, Donahoe PK and MacLaughlin DT: Diagnostic utility of Müllerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors. Gynecol Oncol 73: 51-55, 1999.
33. Kevenaar ME, Themmen AP, van Kerkwijk AJ, Valkenburg O, Uitterlinden AG, de Jong FH, Laven JS and Visser JA: Variants in the ACVR1 gene are associated with AMH levels in women with polycystic ovary syndrome. Hum Reprod 24: 241-249, 2009.